[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100555831":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":43,"centralContacts":44,"locations":50,"responsibleParty":90,"collaborators":43,"id":92,"slug":43,"hasResults":93,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":43,"eligibilityCriteria":97,"healthyVolunteers":93,"sex":98,"minAge":99,"maxAge":43,"enrollmentInfo":100,"targetDuration":43,"studyType":103,"phases":104,"briefSummary":106,"conditions":107,"keywords":110,"overallStatus":53,"whyStopped":43,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},{"fullName":5,"class":6},"Mahidol University","OTHER",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"placebo","PLACEBO_COMPARATOR","placebo 1 tablet\u002Fday for 28 days",[13],"Drug: Placebo",{"label":15,"type":16,"description":17,"interventionNames":18},"olanzapine 2.5","ACTIVE_COMPARATOR","olanzapine 2.5 mg\u002Fday for 28 days",[19],"Drug: Olanzapine 2.5 MG",{"label":21,"type":16,"description":22,"interventionNames":23},"olanzapine 5","olanzapine 5 mg\u002Fday for 28 days",[24],"Drug: Olanzapine 5 MG",[26,32,37],{"type":27,"name":28,"description":17,"armGroupLabels":29,"otherNames":30},"DRUG","Olanzapine 2.5 MG",[15],[31],"OLN2.5",{"type":27,"name":33,"description":22,"armGroupLabels":34,"otherNames":35},"Olanzapine 5 MG",[21],[36],"OLN5",{"type":27,"name":38,"description":39,"armGroupLabels":40,"otherNames":41},"Placebo","placebo 1 tab\u002Fday for 28 days",[9],[42],"PLC",null,[45],{"name":46,"role":47,"phone":48,"phoneExt":43,"email":49},"Suthinee Ithimakin, MD","CONTACT","+66824194489","aesi105@yahoo.co.th",[51,68],{"facility":52,"status":53,"city":54,"state":43,"zip":55,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"Faculty of Medicine Siriraj Hospital","RECRUITING","Bangkok","10260","Thailand","TH",{"type":59,"coordinates":60},"Point",[61,62],100.50144,13.75398,{"lat":62,"lon":61},[65],{"name":66,"role":47,"phone":67,"phoneExt":43,"email":49},"Suthinee Ithimakin","0898127440",{"facility":69,"status":53,"city":54,"state":43,"zip":70,"country":56,"countryCode":57,"cosmosGeoPoint":71,"geoPoint":73,"contacts":74},"Division of medical oncology, department of medicine Siriraj Hospital","10700",{"type":59,"coordinates":72},[61,62],{"lat":62,"lon":61},[75,77,79,82,84,86,88],{"name":46,"role":47,"phone":76,"phoneExt":43,"email":49},"662-419-4489",{"name":46,"role":78,"phone":43,"phoneExt":43,"email":43},"PRINCIPAL_INVESTIGATOR",{"name":80,"role":81,"phone":43,"phoneExt":43,"email":43},"Apirom Laocharoenkeat, MS","SUB_INVESTIGATOR",{"name":83,"role":81,"phone":43,"phoneExt":43,"email":43},"Akarin Nimmannit, MD",{"name":85,"role":81,"phone":43,"phoneExt":43,"email":43},"Ruamporn Kaewvichit, MD",{"name":87,"role":81,"phone":43,"phoneExt":43,"email":43},"Pinyo Sriveerachai, MD",{"name":89,"role":81,"phone":43,"phoneExt":43,"email":43},"Pornpoj Pramyothin, MD",{"type":91,"investigatorFullName":43,"investigatorTitle":43,"investigatorAffiliation":43,"oldNameTitle":43,"oldOrganization":43},"SPONSOR","100555831",false,"NCT06517199","Olanzapine for Cancer Related Anorexia-cachexia Syndrome","Randomized Placebo-controlled Study of Olanzapine for Cancer Related Anorexia-cachexia Syndrome","Inclusion Criteria:\n\n* pathologically or cytologically metastatic or locally advanced cancer\n* anorexia and \\>=5% weight loss during the past 6 months or anorexia with numerical scale of anorexia \\>=5\n* ECOG performance status 0-3\n* able to complete questionaire and able to swallow pills\n\nExclusion Criteria:\n\n* receiving chemotherapy or anti-cancer systemic therapy\n* life expectancy longer than 1 month\n* received radiotherapy at head\u002Fneck or thoracic or upper abdomen in the past 2 weeks\n* surgery within 4 weeks\n* pregnancy\n* serum bilirubin \\> 2 mg\u002Fdl or serum Cr \\> 2 mg\u002Fdl\n* current use of olanzapine or other antipsychotic drug\n* known cardiac arrhythmia, uncontrolled brain metastasis, history of seizure or acute coronary event in the past 6 months","ALL","18 Years",{"count":101,"type":102},138,"ESTIMATED","INTERVENTIONAL",[105],"PHASE3","Cancer anorexia-cachexia syndrome is one of the common conditions in cancer patients. Olanzapine has been demonstrated to reduce chemotherapy-induced anorexia. However, there is scarce information regarding olanzapine as a treatment of cancer anorexia among patients who does not receive chemotherapy. Therefore, this randomized controlled trial aims to evaluate the efficacy of olanzapine to lessen cancer cachexia-anorexia syndrome.",[108,109],"Anorexia","Cachexia",[111,112],"cancer anorexia","olanzapine","2024-07-18",{"date":115,"type":116},"2024-07-24","ACTUAL",{"date":118,"type":116},"2024-01-22",{"date":120,"type":102},"2026-01-21",{"name":5,"class":6},2]